Not Yet Recruiting
ASCiminib, With or Without Dasatinib Combination, as a 2nd-Line Therapy to ADVANCE the Treatment for Chronic Myelogenous Leukemia in Chronic Phase (ASC2ADVANCE)
NCT07538401
- Conditions
- Bone Marrow Diseases, Chronic Disease, Chronic Myeloid Leukemia (CML) in, +11 more
- Locations
-
Not specified